You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePemetrexed
Accession NumberDB00642  (APRD00573, EXPT02075)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionPemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
Structure
Thumb
SynonymsNot Available
External IDs LY-231514 / LY231514 / NSC-698037
Product Ingredients
IngredientUNIICASInChI KeyDetails
Pemetrexed disodium2PKU919BA9 150399-23-8NYDXNILOWQXUOF-GXKRWWSZSA-LDetails
Pemetrexed disodium hemipentahydrateF4GSH45R4C 357166-30-4ZCTCZKWJFTYNMZ-WKUCUCPSSA-JDetails
Pemetrexed disodium heptahydrate9T47E4OM16 357166-29-1QJVSMHJWAOSBMD-MYXYZBIASA-LDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act PemetrexedPowder, for solution100 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act PemetrexedPowder, for solution500 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
Act PemetrexedPowder, for solution1000 mgIntravenousActavis Pharma CompanyNot applicableNot applicableCanada
AlimtaPowder, for solution100 mgIntravenousEli Lilly & Co. Ltd.2009-01-09Not applicableCanada
AlimtaInjection, powder, for solution500 mgIntravenousEli Lilly Nederland B.V.2004-09-20Not applicableEu
AlimtaInjection, powder, for solution100 mgIntravenousEli Lilly Nederland B.V.2004-09-20Not applicableEu
AlimtaInjection, powder, lyophilized, for solution500 mg/20mLIntravenousEli Lilly & Co. Ltd.2004-02-04Not applicableUs
AlimtaInjection, powder, lyophilized, for solution100 mg/4mLIntravenousEli Lilly & Co. Ltd.2007-09-07Not applicableUs
AlimtaPowder, for solution500 mgIntravenousEli Lilly & Co. Ltd.2004-08-03Not applicableCanada
PemetrexedPowder, for solution500 mgIntravenousApotex CorporationNot applicableNot applicableCanada
PemetrexedPowder, for solution100 mgIntravenousApotex CorporationNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution100 mgIntravenousTevaNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution100 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution100 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution500 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution500 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution100 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution500 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution1000 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution500 mgIntravenousTevaNot applicableNot applicableCanada
Pemetrexed Disodium for InjectionPowder, for solution1000 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Taro-pemetrexedPowder, for solution100 mgIntravenousTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Taro-pemetrexedPowder, for solution500 mgIntravenousTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CiambraInjection, powder, for solution500 mgIntravenousMenarini International Operations Luxembourg S.A.2015-12-02Not applicableEu
CiambraInjection, powder, for solution100 mgIntravenousMenarini International Operations Luxembourg S.A.2015-12-02Not applicableEu
Pemetrexed Accord Solution for InfusionPowder, for solution1000 mgIntravenousAccord Healthcare Limited2016-01-18Not applicableEu
Pemetrexed HospiraInjection, powder, for solution100 mgIntravenousHospira, Inc.2015-11-20Not applicableEu
Pemetrexed HospiraInjection, powder, for solution500 mgIntravenousHospira, Inc.2015-11-20Not applicableEu
Pemetrexed HospiraInjection, powder, for solution000 mgIntravenousHospira, Inc.2015-11-20Not applicableEu
Pemetrexed LillyInjection, powder, for solution500 mgIntravenousEli Lilly Netherlands2015-09-14Not applicableEu
Pemetrexed LillyInjection, powder, for solution100 mgIntravenousEli Lilly Netherlands2015-09-14Not applicableEu
Pemetrexed MedacInjection, powder, for solution100 mgIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2015-11-27Not applicableEu
Pemetrexed MedacInjection, powder, for solution1000 mgIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2015-11-27Not applicableEu
Pemetrexed MedacInjection, powder, for solution500 mgIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2015-11-27Not applicableEu
Pemetrexed SandozPowder, for solution1000 mgIntravenousSandoz2015-09-18Not applicableEu
Pemetrexed SandozInjection, powder, for solution100 mgIntravenousSandoz2015-09-18Not applicableEu
Pemetrexed SandozInjection, powder, for solution500 mgIntravenousSandoz2015-09-18Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII04Q9AIZ7NO
CAS number137281-23-3
WeightAverage: 427.4106
Monoisotopic: 427.149183429
Chemical FormulaC20H21N5O6
InChI KeyWBXPDJSOTKVWSJ-ZDUSSCGKSA-N
InChI
InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1
IUPAC Name
(2S)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
SMILES
[H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Pharmacology
IndicationUsed in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Structured Indications
PharmacodynamicsPreclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin.
Mechanism of actionPemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Thymidylate synthaseProteinyes
inhibitor
HumanP04818 details
Bifunctional purine biosynthesis protein PURHProteinyes
inhibitor
HumanP31939 details
Dihydrofolate reductaseProteinyes
inhibitor
HumanP00374 details
Trifunctional purine biosynthetic protein adenosine-3Proteinyes
inhibitor
HumanP22102 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 16.1 L
Protein binding81%
Metabolism

Metabolized by Cytochrome P450 Enzymes

Route of eliminationPemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration.
Half life3.5 hours
Clearance
  • 91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.Approved
ClozapineThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pemetrexed.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pemetrexed.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Pemetrexed.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.Approved, Investigational
FingolimodPemetrexed may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Pemetrexed is combined with G17DT.Investigational
INGN 201The risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pemetrexed.Withdrawn
NatalizumabThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Pemetrexed.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Pemetrexed.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pemetrexed.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Pemetrexed is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Pemetrexed.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.Approved
SRP 299The risk or severity of adverse effects can be increased when Pemetrexed is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed.Approved, Investigational
TofacitinibPemetrexed may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pemetrexed.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US5344932
General References
  1. Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. [PubMed:16291410 ]
  2. Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic]. Bull Cancer. 2007;94 Spec No Actualites:S134-8. [PubMed:17845983 ]
  3. Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. [PubMed:20446853 ]
  4. Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. [PubMed:12722874 ]
External Links
ATC CodesL01BA04
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (233 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Lymphoproliferative Disorders / Metastatic Cancers / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis / Unspecified Adult Solid Tumor, Protocol Specific1
0RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers2
1Active Not RecruitingTreatmentCancers2
1Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
1Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
1Active Not RecruitingTreatmentRecurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentStage IV Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdvanced Non-Small Cell Lung Cancer / Lung Cancer, Non-Small Cell1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumours / Cancers / Lung Cancer, Non-Small Cell1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma of the Prostate / Esophageal Cancers / Gastric Cancers / Head and Neck Cancers / Lung Cancers1
1CompletedTreatmentCancer, Breast / Carcinoma of the Prostate / Colorectal Cancers / Head and Neck Cancers / Lung Cancers / Mesothelioma / Pancreatic Cancers / Sarcomas1
1CompletedTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Lung Cancers1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1CompletedTreatmentCancers3
1CompletedTreatmentCancers / Metastases1
1CompletedTreatmentCarcinomas / Lung Cancers / Non-Small Cell Lung1
1CompletedTreatmentCentral Nervous System Lymphoma1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentHead and Neck Cancers2
1CompletedTreatmentInoperable Non Small Cell Lung Cancer1
1CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV1
1CompletedTreatmentLymphoma NOS / Tumors, Solid1
1CompletedTreatmentMesothelioma2
1CompletedTreatmentNeoplasms4
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)2
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)4
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / KRAS Gene Mutation / Lung Cancers1
1Not Yet RecruitingTreatmentCarcinoma of the Lungs / Lungcancer1
1Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingOtherMesothelioma1
1RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced1
1RecruitingTreatmentBladder Cancers / Cancer, Ovarian / Mesothelioma / Non-Small-Cell Lung Carcinoma (NSCLC) / Peritoneal Cancer / Thymoma / Thymus Cancer / Uterine Cervical Cancer1
1RecruitingTreatmentCancer, Advanced / Mesothelioma, Malignant / Metastatic Breast Cancer (MBC) / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL) / Non-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Pancreatic Cancers / Tumors1
1RecruitingTreatmentHead and Neck Cancers / Salivary Gland Tumors1
1RecruitingTreatmentMetastatic Malignant Neoplasm in the Brain / Stage IIIA Large Cell Lung Carcinoma / Stage IIIA Lung Adenocarcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Large Cell Lung Carcinoma / Stage IIIB Lung Adenocarcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Large Cell Lung Carcinoma / Stage IV Lung Adenocarcinoma / Stage IV Non-Small Cell Lung Cancer1
1RecruitingTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
1RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentOncology, Medical1
1RecruitingTreatmentPleural Mesotheliomas1
1RecruitingTreatmentStage IV Lung Adenocarcinoma1
1TerminatedTreatmentAdvanced Solid Malignancies / Cancers / Tumors, Solid1
1TerminatedTreatmentLymphoma NOS1
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
1TerminatedTreatmentNonsmall Cell Lung Cancer Stage III / Nonsquamous Nonsmall Cell Neoplasm of Lung1
1TerminatedTreatmentPancreatic Cancers1
1WithdrawnTreatmentAdvanced Solid Tumors1
1WithdrawnTreatmentCancers / Neoplasms / Tumors1
1WithdrawnTreatmentLung Cancers1
1WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
1WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentAdvanced Malignant Mesothelioma / Epithelioid Mesothelioma / Pleural Malignant Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatoid Mesothelioma1
1, 2Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM) / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentAdvanced Carcinoma / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentCancer, Advanced / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Breast / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cancer1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentExtrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer1
1, 2CompletedTreatmentLung Cancers / Non-Small-Cell Lung Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific2
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
1, 2CompletedTreatmentMalignant Pleural Mesothelioma (MPM) / Tumors, Solid1
1, 2CompletedTreatmentMalignant Pleural Mesotherioma1
1, 2CompletedTreatmentNeoplasm, Gastric1
1, 2CompletedTreatmentNeoplasms, Lung1
1, 2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)3
1, 2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
1, 2CompletedTreatmentRectal Cancers1
1, 2CompletedTreatmentTransitional Cell Carcinoma1
1, 2CompletedTreatmentUrologic Neoplasms1
1, 2Not Yet RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)1
1, 2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Advanced Peritoneal Malignant Mesothelioma / Advanced Pleural Malignant Mesothelioma / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Peritoneal Malignant Mesothelioma / Recurrent Pleural Malignant Mesothelioma / Recurrent Solid Neoplasm / Solid Neoplasms / Stage III Non-Small Cell Lung Cancer / Stage III Ovarian Cancer / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Ovarian Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Pleural Mesothelioma / Thymoma / Unresectable Solid Neoplasm1
1, 2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
1, 2RecruitingTreatmentTo Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy1
1, 2TerminatedTreatmentCarcinoma, Small Cell / SCLC / Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentHead and Neck Cancers1
1, 2TerminatedTreatmentMesothelioma1
1, 2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
1, 2Unknown StatusTreatmentNon Small Cell Lung Cancer (NSCLC)1
1, 2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Metastatic Cancers1
2Active Not RecruitingTreatmentLung Cancers4
2Active Not RecruitingTreatmentLung Cancers / Neoplasms Metastasis1
2Active Not RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingTreatmentMesothelioma, Malignant2
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Nonsquamous Nonsmall Cell Neoplasm of Lung1
2Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
2Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
2Active Not RecruitingTreatmentNonsquamous Nonsmall Cell Neoplasm of Lung1
2Active Not RecruitingTreatmentRecurrent Non-small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Approved for MarketingNot AvailableMesothelioma1
2CompletedNot AvailableMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Nonsquamous Non-Small Cell Neoplasm of Lung1
2CompletedDiagnosticCancers1
2CompletedPreventionHistological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Lung1
2CompletedTreatmentAdenocarcinoma of the Lung / Metastases, Brain1
2CompletedTreatmentAdenocarcinomas1
2CompletedTreatmentAdenocarcinomas / Non-Small-Cell Lung Cancer (NSCLC)1
2CompletedTreatmentAdvanced Gastric Carcinoma1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBreast Neoplasms, Male / Cancer, Breast / Ductal Carcinoma1
2CompletedTreatmentCancer of Endometrium / Cancer of the Endometrium / Endometrial Cancers / Endometrium Cancer / Genital Neoplasms, Female / Neoplasms / Neoplasms by Site / Neoplasms, Endometrial / Urogenital Neoplasms / Uterine Neoplasms1
2CompletedTreatmentCancer, Breast6
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancers1
2CompletedTreatmentCarcinoma of the Prostate1
2CompletedTreatmentCarcinoma, Small Cell1
2CompletedTreatmentCarcinoma, Urothelial1
2CompletedTreatmentCarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentCervical Cancers2
2CompletedTreatmentCervical Intraepithelial Neoplasias / Genital Neoplasms, Female / Uterine Neoplasms1
2CompletedTreatmentChoriocarcinoma / Hydatidiform Mole / Trophoblastic Neoplasms / Uterine Neoplasms1
2CompletedTreatmentColorectal Cancers2
2CompletedTreatmentEndometrial Cancers1
2CompletedTreatmentEpendymomas / Medulloblastomas / Neuroblastoma (Measurable Disease) / Neuroblastoma (Metaiodobenzylguanidine / Non-brainstem High-grade Glioma / Osteosarcomas / Positive Evaluable) / Rhabdomyosarcomas / Sarcoma, Ewing's1
2CompletedTreatmentGastric Cancers2
2CompletedTreatmentHead and Neck Cancers4
2CompletedTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancer, Non-Small Cell1
2CompletedTreatmentLung Cancers20
2CompletedTreatmentLung Cancers / Metastatic Cancers1
2CompletedTreatmentLung Cancers / Non Small Cell Lung Cancer (NSCLC)2
2CompletedTreatmentLung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)2
2CompletedTreatmentMesothelioma4
2CompletedTreatmentMesothelioma, Malignant2
2CompletedTreatmentMesothelioma / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMetastatic Colorectal Cancers2
2CompletedTreatmentMetastatic Non-squamous Non Small Cell Lung Cancer1
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNeoplasm Metastases / Urologic Neoplasms1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Gastrointestinal1
2CompletedTreatmentNeoplasms, Head and Neck2
2CompletedTreatmentNeoplasms, Lung1
2CompletedTreatmentNeoplasms, Ovarian / Primary Peritoneal Cancer1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)13
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)5
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)19
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer2
2CompletedTreatmentOsteosarcomas1
2CompletedTreatmentOvarian Carcinoma / Primary Peritoneal Carcinoma1
2CompletedTreatmentPancreatic Cancers1
2CompletedTreatmentPleural Neoplasms1
2CompletedTreatmentPrevious Treated Metastatic Non-small Cell Lung Cancer1
2CompletedTreatmentPreviously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer1
2CompletedTreatmentRectal Neoplasms1
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer1
2CompletedTreatmentSarcomas2
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentThymic Carcinoma / Thymoma1
2CompletedTreatmentUrologic Neoplasms1
2Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
2Not Yet RecruitingTreatmentBladder Cancers / Urothelial Cancer1
2Not Yet RecruitingTreatmentColo-rectal Cancer1
2Not Yet RecruitingTreatmentColorectal Cancers1
2Not Yet RecruitingTreatmentEGFR Gene Mutation / Nonsmall Cell Lung Cancer1
2Not Yet RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2Not Yet RecruitingTreatmentMetastases, Brain1
2Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
2RecruitingDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous Cell Carcinoma of the Cervix1
2RecruitingTreatmentAdenocarcinoma of the Lung1
2RecruitingTreatmentAdenocarcinoma of the Lung / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Large Cell / Heregulin / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Lung1
2RecruitingTreatmentAdvanced NSCLC1
2RecruitingTreatmentAdvanced Stage IIIB / High Thymidylate Synthase Expression / Non-Small-Cell Lung Carcinoma (NSCLC) / Secondary1
2RecruitingTreatmentBevacizumab / Metastases, Brain / Non Squamous Non-small Cell Lung Cancer1
2RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCarcinoma, Non-squamous Non-small-cell Lung1
2RecruitingTreatmentEGFR Mutations / Metastases, Brain / Non-Small-Cell Lung Carcinoma (NSCLC)1
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM)1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentMesothelioma2
2RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
2RecruitingTreatmentMetastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
2RecruitingTreatmentNon-small-cell Lung Cancer With Somatic EGFR Mutations1
2RecruitingTreatmentSquamous Cell Lung Cancer1
2RecruitingTreatmentStage IV Non-Small Cell Lung Cancer1
2SuspendedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedDiagnosticMalignant Pleural Mesothelioma (MPM) / Pleural Mesotheliomas1
2TerminatedTreatmentCancer, Ovarian / Peritoneal Cancer1
2TerminatedTreatmentCarcinoma, Small Cell1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentGestational Trophoblastic Disease1
2TerminatedTreatmentHead and Neck Cancers1
2TerminatedTreatmentLung Cancer - Non Small Cell1
2TerminatedTreatmentLung Cancer, Small Cell1
2TerminatedTreatmentLung Cancers6
2TerminatedTreatmentMesothelioma, Malignant1
2TerminatedTreatmentMesothelioma / Pleural Mesotheliomas1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms, Esophageal1
2TerminatedTreatmentNeoplasms, Lung1
2TerminatedTreatmentNon Small Cell Lung Cancer (NSCLC)1
2TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)3
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)8
2TerminatedTreatmentNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer / Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentPancreas Cancer1
2TerminatedTreatmentRecurrent Non Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRenal Cell Carcinoma (RCC)1
2TerminatedTreatmentSmall Cell Lung Cancer (SCLC)3
2Unknown StatusTreatmentAdvanced Non-Small Cell Lung Cancer1
2Unknown StatusTreatmentMalignant / Mesothelioma / Pleural1
2Unknown StatusTreatmentNon Small Cell Lung Cancer (NSCLC)3
2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)5
2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Toxicity1
2Unknown StatusTreatmentPleural Mesotheliomas1
2Unknown StatusTreatmentSquamous Cell Carcinoma of Head and Neck1
2Unknown StatusTreatmentThyroid Cancers1
2Unknown StatusTreatmentTumors, Central Nervous System1
2Unknown StatusTreatmentUntreated Advanced Non-Small Cell Lung Cancer1
2WithdrawnTreatmentAdvanced Malignant Mesothelioma / Epithelial Mesothelioma / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma1
2WithdrawnTreatmentCancer of Head and Neck1
2WithdrawnTreatmentEsophagogastric Cancer1
2WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2WithdrawnTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2WithdrawnTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentStage III Non-Small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent / Non-Small-Cell Lung Carcinoma (NSCLC) / Progression of Non-small Cell Lung Cancer1
2, 3CompletedTreatmentMesothelioma1
2, 3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3RecruitingTreatmentMesothelioma1
2, 3TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingPreventionNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentAdvanced Non Small Cell Lung Cancer1
3Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentLung Cancers2
3Active Not RecruitingTreatmentLung Cancers / Non Small Cell Lung Cancer (NSCLC)1
3Active Not RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB1
3Active Not RecruitingTreatmentNSCLC (Non-Small Cell Lung Cancer)1
3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (Squamous or Non Squamous)1
3Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)7
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage IV or Recurrent Non-Small Cell Lung Cancer1
3CompletedTreatmentLung Cancers1
3CompletedTreatmentMesothelioma1
3CompletedTreatmentMesothelioma, Malignant1
3CompletedTreatmentNeoplasm Metastases / Neoplasms, Pancreatic1
3CompletedTreatmentNeoplasms, Head and Neck1
3CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)5
3CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)2
3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)9
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer3
3CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
3Enrolling by InvitationTreatmentCancers1
3Enrolling by InvitationTreatmentEGFR Gene Mutation1
3Not Yet RecruitingTreatmentCarcinoma,Non-Small-Cell Lung / Lung Carcinomas, Non-Small-Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer1
3Not Yet RecruitingTreatmentMalignant Hydrothorax / Non Small Cell Lung Cancer (NSCLC)1
3Not Yet RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingNot AvailableAdenocarcinoma of Lung Metastatic to Brain / Bevacizumab / Brain Radiotherapy / Cerebral Metastases / Cerebral Radiotherapy / Metastatic Non-Small Cell Lung Cancer / Non Epidermoid / Non-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentAnaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentFirst Line Non-Small Cell Lung Cancer1
3RecruitingTreatmentMesothelioma2
3RecruitingTreatmentMetastatic Non-Squamous Non-Small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNeoplasms, Lung1
3RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)2
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)4
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer / Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer1
3RecruitingTreatmentOligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer(NSCLC)1
3TerminatedTreatmentLung Cancers / Neoplasms, Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Pulmonary Neoplasms1
3TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
3Unknown StatusTreatmentLung Cancers1
3Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3Unknown StatusTreatmentNon-squamous Nonsmall Cell Neoplasm of Lung1
4CompletedTreatmentLocally Advanced Malignant Neoplasm1
4CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
4CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
4CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
4Not Yet RecruitingTreatmentAdenocarcinoma of the Lung1
4RecruitingTreatmentAdenocarcinoma of Lung1
4RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer2
4RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
Not AvailableCompletedNot AvailableNeoplasms, Lung1
Not AvailableCompletedNot AvailableNon Small Cell Lung Cancer (NSCLC)1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
Not AvailableTerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableUnknown StatusScreeningNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableUnknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous100 mg/4mL
Injection, powder, lyophilized, for solutionIntravenous500 mg/20mL
Powder, for solutionIntravenous100 mg
Powder, for solutionIntravenous500 mg
Injection, powder, for solutionIntravenous100 mg
Injection, powder, for solutionIntravenous500 mg
Powder, for solutionIntravenous1000 mg
Injection, powder, for solutionIntravenous000 mg
Injection, powder, for solutionIntravenous1000 mg
Prices
Unit descriptionCostUnit
Alimta 500 mg Solution Vial3154.94USD vial
Alimta 500 mg vial3033.6USD vial
Alimta 100 mg vial606.72USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1340794 No1999-10-192016-10-19Canada
CA2400155 No2009-09-152021-02-12Canada
US5217974 No1994-03-292011-03-29Us
US5344932 Yes1997-01-242017-01-24Us
US7772209 Yes2002-05-242022-05-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0905 mg/mLALOGPS
logP-0.19ALOGPS
logP-0.25ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.34ChemAxon
pKa (Strongest Basic)7.13ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area187.96 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity120.46 m3·mol-1ChemAxon
Polarizability43.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6997
Blood Brain Barrier+0.7542
Caco-2 permeable-0.819
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.9729
P-glycoprotein inhibitor IINon-inhibitor0.9825
Renal organic cation transporterNon-inhibitor0.8923
CYP450 2C9 substrateNon-substrate0.7547
CYP450 2D6 substrateNon-substrate0.8204
CYP450 3A4 substrateNon-substrate0.6051
CYP450 1A2 substrateNon-inhibitor0.912
CYP450 2C9 inhibitorNon-inhibitor0.8938
CYP450 2D6 inhibitorNon-inhibitor0.9117
CYP450 2C19 inhibitorNon-inhibitor0.8844
CYP450 3A4 inhibitorNon-inhibitor0.8253
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9508
Ames testNon AMES toxic0.8528
CarcinogenicityNon-carcinogens0.964
BiodegradationNot ready biodegradable0.8296
Rat acute toxicity2.5023 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9624
hERG inhibition (predictor II)Non-inhibitor0.8718
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentGlutamic acid and derivatives
Alternative Parents
Substituents
  • Glutamic acid or derivatives
  • Hippuric acid or derivatives
  • Hippuric acid
  • N-acyl-alpha-amino acid
  • N-acyl-alpha amino acid or derivatives
  • Pyrrolopyrimidine
  • Benzamide
  • Pyrrolo[2,3-d]pyrimidine
  • Benzoic acid or derivatives
  • Benzoyl
  • Pyrimidone
  • Aminopyrimidine
  • Dicarboxylic acid or derivatives
  • Benzenoid
  • Monocyclic benzene moiety
  • Pyrimidine
  • Substituted pyrrole
  • Heteroaromatic compound
  • Vinylogous amide
  • Pyrrole
  • Amino acid
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid
  • Organoheterocyclic compound
  • Organic nitrogen compound
  • Amine
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887 ]
  2. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
  3. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245 ]
  4. Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712 ]
  5. Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. [PubMed:11763166 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474 ]
  8. Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793 ]
  9. Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699 ]
  10. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
  11. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).
Gene Name:
ATIC
Uniprot ID:
P31939
Molecular Weight:
64615.255 Da
References
  1. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]
  2. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
  3. Racanelli AC, Rothbart SB, Heyer CL, Moran RG: Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009 Jul 1;69(13):5467-74. doi: 10.1158/0008-5472.CAN-08-4979. Epub 2009 Jun 23. [PubMed:19549896 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
  2. Norman P: Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs. 2001 Nov;2(11):1611-22. [PubMed:11763166 ]
  3. Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, Noordhuis P, Bunni MA, Rosowsky A, Schornagel JH, Pinedo HM, Jansen G: Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol. 2002 Jan 15;63(2):105-15. [PubMed:11841783 ]
  4. Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474 ]
  5. Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887 ]
  8. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245 ]
  9. Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712 ]
  10. Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699 ]
  11. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
  12. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phosphoribosylglycinamide formyltransferase activity
Specific Function:
Not Available
Gene Name:
GART
Uniprot ID:
P22102
Molecular Weight:
107766.295 Da
References
  1. Schultz RM, Dempsey JA: Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. Anticancer Res. 2001 Sep-Oct;21(5):3209-14. [PubMed:11848474 ]
  2. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6(4):363-73. [PubMed:11524555 ]
  3. Molina JR, Adjei AA: The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul;5(1):21-7. [PubMed:14596699 ]
  4. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. 2005 Jul;68(1):110-8. Epub 2005 Mar 28. [PubMed:15795320 ]
  5. Kindler HL: Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. [PubMed:12571811 ]
  6. Adjei AA: Gemcitabine and Pemetrexed disodium in treating breast cancer. Oncology (Williston Park). 2001 Feb;15(2 Suppl 3):34-7. [PubMed:11252887 ]
  7. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. [PubMed:11531245 ]
  8. Adjei AA: Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung Cancer. 2001 Dec;34 Suppl 4:S103-5. [PubMed:11742712 ]
  9. Adjei AA: Pemetrexed in the treatment of selected solid tumors. Semin Oncol. 2002 Apr;29(2 Suppl 5):50-3. [PubMed:12023793 ]
  10. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Protein homodimerization activity
Specific Function:
Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
Gene Name:
DCK
Uniprot ID:
P27707
Molecular Weight:
30518.315 Da
References
  1. De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F: Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818. [PubMed:21336182 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Nucleoside transmembrane transporter activity
Specific Function:
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
Gene Name:
SLC29A1
Uniprot ID:
Q99808
Molecular Weight:
50218.805 Da
References
  1. De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, De Braud F: Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. J Thorac Oncol. 2011 Apr;6(4):768-73. doi: 10.1097/JTO.0b013e31820d7818. [PubMed:21336182 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 27, 2017 07:22